Polypid targets rolling NDA submission for D-PLEX100 by end of Q1 2026 amid advanced U.S. partnership talks
Source: SeekingAlpha
2026-02-11 15:25:17 ET
More on PolyPid
- PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript
- PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript
- Seeking Alpha’s Quant Rating on PolyPid
- Historical earnings data for PolyPid
- Financial information for PolyPid
Read the full article on Seeking Alpha
For further details see:
Polypid targets rolling NDA submission for D-PLEX100 by end of Q1 2026 amid advanced U.S. partnership talks
PolyPid Ltd.
NASDAQ: PYPD
PYPD Trading
-2.83% G/L:
$4.29 Last:
22,488 Volume:
$4.42 Open:
PYPD Latest News
February 11, 2026 07:30:00 am
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
PYPD Stock Data
$48,610,612
10,017,659
N/A
8
N/A
Biotechnology & Life Sciences
Healthcare
IL
Petach Tikva
